Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Kin Meds vs Oak

Kin Meds
Graded #73

Lower grade

vs+3
Oak
Graded #42

Higher grade

The verdict

Oak takes it — 75.9/100 to 72.9/100.

Oak grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. The cheapest published prices on the board, sold as a package with no membership fee.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueOak +22
74
96
Dose & formulationKin Meds +31
93
62
Clinical oversightKin Meds +8
74
66
Labs & monitoringOak +5
53
58
FulfillmentOak +16
72
88
Contract termsOak +33
55
88
Kin Meds · left barOak · right bar

The numbers

MetricKin MedsOak
WeighScore72.9/10075.9/100
GradeCC
Scorecard rank#73#42
Semaglutide$149/mo (brand Wegovy)From $119/mo
Tirzepatide$149/mo (brand Zepbound)From $185/mo
CoverageCoverage not publishedAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
Kin Meds

Graded #73 · C

Strengths

  • Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
  • Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
  • LegitScript verified
  • Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
  • Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health

Where it loses points

  • Legal entity name and state of incorporation not publicly disclosed
  • The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
  • Per-state availability not listed
  • $149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
  • Lab work and dose-titration support not clearly described
Oak

Graded #42 · C

Strengths

  • Lowest published prices here — semaglutide from $119/mo, tirzepatide from $185/mo
  • One price across every dosage, so titrating up costs no more
  • No membership or subscription fee, and free shipping
  • All 50 states, offered in Spanish as well as English

Where it loses points

  • Same-day approval with no video call means very little clinical contact before a prescription
  • No published lab or monitoring programme
  • Injection only, and no brand-name lane
  • Sold as packages, so re-ordering is on you

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard